Effect of calculation method on kidney dosimetry in ¹⁷⁷Lu-octreotate treatment

References

• Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med 2001;28:1319–25.
   PubMedGoogle Scholar
• Öberg K, Knigge U, Kwekkeboom D, Perren A, ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii124–30.
   PubMed Web of Science ®Google Scholar
• Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014;53:1284–97.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53–73.
   PubMed Web of Science ®Google Scholar
• Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging 2014;41:1845–51.
   PubMed Web of Science ®Google Scholar
• Larsson M, Bernhardt P, Svensson JB, Wängberg B, Ahlman H, Forssell-Aronsson E. Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Research 2012;2:49–61.
   PubMed Web of Science ®Google Scholar
• Kam BLR, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39:S103–12.
   PubMed Web of Science ®Google Scholar
• Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010;116:1084–92.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. 177Lu-DOTATATE significantly improves progression-free survival in patients with mid-gut neuroendocrine tumours: results of the phase III NETTER-1 trial [abstract LBA 6]. Presented at the ECC; 2015.
   Google Scholar
• Vegt E, de Jong M, Wetzels J, Masereeuw R, Melis M, Oyen W, et al. Renal toxicity of radiolabelled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2015;51:1049–58.
   Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTANOC and 177Lu DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847–56.
   PubMed Web of Science ®Google Scholar
• Thompson PL, Mackay IR, Robson GS, et al. Late radiation nephritis after gastric x-irradiation for peptic ulcer. Q J Med 1971;40:145–57.
   PubMedGoogle Scholar
• Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individual dosimetry of patients undergoing therapy with 177Lu-DOTA-D-Phe-Tyr-octreotate. Eur J Nucl Med Mol Imaging 2010;37:212–25.
   PubMed Web of Science ®Google Scholar
• Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007;22:406–16.
   PubMed Web of Science ®Google Scholar
• Barone R, Borson-Chazot F, Valkema R, Walrandt S, Chaufin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:995–1065.
   Web of Science ®Google Scholar
• Garske U, Sandström M, Johansson S, Sundin A, Granberg D, Eriksson B, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol 2012;51:86–96.
   PubMed Web of Science ®Google Scholar
• Garske U, Sandström M, Johansson S, Granberg D, Lundqvist H, Lubberink M, et al. Lessons on tumour response: imaging during therapy with (177)Lu-DOTA-octreotate. A case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma. Theranostics 2012;2:459–71.
   PubMed Web of Science ®Google Scholar
• Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46:83S–91S.
   PubMed Web of Science ®Google Scholar
• Sandström M, Garske-Roman U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med 2013;54:33–41.
   PubMed Web of Science ®Google Scholar
• Hippelainen E, Tenhunen M, Maenpaa H, Sohlberg A. Quantitative accuracy of Lu-177 SPECT reconstruction using different compensation methods: phantom and patient studies. EJNMMI Res 2016;6:16–23.
   PubMed Web of Science ®Google Scholar
• Cremonesi M, Ferrari M, Bodei L, Bartolomei M, Chinol M, Mei R, et al. Dosimetry in patients undergoing 177Lu-DOTATATE therapy with indications for 90Y-DOTATATE. Eur J Nucl Med Mol Imaging 2006;33:s102.
   Web of Science ®Google Scholar
• Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Mol Imaging 2010;54:37–51.
   PubMed Web of Science ®Google Scholar
• Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134–42.
   PubMed Web of Science ®Google Scholar